Get started
ARGENX SEARGENX SEARGENX SE

ARGENX SE

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Forecast Seasonals

ARGX trade ideas

Argenx (ARGX) AnalysisCompany Overview: Argenx NASDAQ:ARGX is making significant strides in the field of autoimmune treatments, especially following the FDA approval of VYVGART Hytrulo for chronic inflammatory demyelinating polyneuropathy (CIDP) on June 21st. This approval not only enhances Argenx's product portfolio but also opens up new revenue channels for the company. Key Developments: Strong Revenue Generation: Argenx demonstrates a robust global presence with revenue streams across various regions: U.S.: $407 million Japan: $20 million EMEA: $35 million China: $14 million This diversified revenue generation helps mitigate regional risks and showcases the company’s ability to penetrate multiple markets effectively. Upcoming Trials: The company plans to launch four new registration trials by the end of 2024, further expanding its therapeutic offerings. This proactive approach to research and development positions Argenx for future growth and diversification in its product line. Strategic Collaboration: Argenx's collaboration with Monarch is aimed at enhancing operational efficiency and customer service. This partnership is expected to boost market penetration and strengthen the company's competitive edge. Investment Outlook: Bullish Outlook: We are bullish on ARGX above the $484.00-$489.00 range, driven by its recent FDA approval, diverse revenue streams, and plans for further clinical expansion. Upside Potential: Our target for Argenx is set at $740.00-$750.00, supported by the company’s strong market presence and growth initiatives. 🚀 ARGX—Pioneering the Future of Autoimmune Treatments. #Biotech #AutoimmuneTherapy #MarketGrowth
NASDAQ:ARGXLong
by Richtv_official
Argenx Lead as Chugai's Muscle Disease Treatment DisappointsIn a whirlwind of market reactions, biotech stocks Argenx ( NASDAQ:ARGX ) and Immunovant ( NASDAQ:IMVT ) emerged as frontrunners on Thursday, propelled by disappointing results from Japanese rival Chugai Pharmaceutical. The contrast in fortunes underscores the high stakes and volatile nature of the biotech industry, where a single clinical trial outcome can send shockwaves through the market. Chugai's Disappointment Ripples Across Biotech Sector: Chugai Pharmaceutical's setback in its muscle disease treatment trial reverberated across the biotech landscape, triggering a surge in Argenx ( NASDAQ:ARGX ) and Immunovant stocks. The underwhelming results of Chugai's study, despite showing statistically significant improvements, fell short of expectations, providing a significant boost to Argenx's Vyvgart, an approved treatment for generalized myasthenia gravis (gMG). Argenx ( NASDAQ:ARGX ) and Immunovant Gain Ground: For Argenx ( NASDAQ:ARGX ) and Immunovant, Chugai's stumble presented a clear opportunity to solidify their positions in the market. With Argenx's Vyvgart already generating substantial revenue and Immunovant's promising Phase 3 drug in the pipeline, investors rallied behind these companies, anticipating significant growth prospects in the wake of Chugai's disappointment. Tourmaline Faces Turmoil Amidst Market Correction: In stark contrast, Tourmaline experienced a sharp downturn as investors recalibrated their expectations in light of Chugai's underwhelming results. Despite earlier optimism surrounding Tourmaline's IL-6 program, the biotech stock's plunge underscores the inherent volatility and uncertainty inherent in the biotech sector. Analyst Insights and Market Dynamics: Leerink Partners analyst Thomas Smith provided valuable insights into Tourmaline's prospects, acknowledging the setback while maintaining an optimistic outlook based on the company's ongoing Phase 2 studies. Meanwhile, Argenx and Immunovant's resilience in the face of market turbulence reflects their strong market positions and growth potential. Strategic Implications and Future Outlook: Chugai's disappointing results not only reaffirm Argenx's leadership in the gMG market but also underscore the importance of innovative treatments in driving growth in the biotech sector. As Argenx ( NASDAQ:ARGX ) and Immunovant continue to capitalize on market opportunities, investors will closely monitor their progress and potential rivalries in the competitive landscape.
NASDAQ:ARGXLong
by DEXWireNews
ARGX Bullish Trade Setup Looking to place some longs on ARGX. Argenx SE operates as a biotechnology company. The Company develops antibody based therapies for the treatment of severe autoimmune diseases and cancer. argenx serves customers in the Netherlands and Belgium.n top 10: 10 8 25.0% 6 (0.35%) 6 (0.35%) 0.0% Funds Holding: 185 170 8.82% 63 (3.7%) 55 (3.19%) 14.55% 13F shares: 28.505 Million 25.49 Million 11.83% 10.773 Million 9.159 Million 17.63% % Ownership 55.9632 53.8414 3.94% 21.1511 19.3456 9.33% New Positions: 32 28 14.29% 14 5 180.0% Increased Positions 84 60 40.0% 25 14 78.57% Closed Positions 15 16 -6.25% 5 4 25.0% Reduced Positions 50 58 -13.79% 17 23 -26.09% Total Calls 225.886 Thousand 215.074 Thousand 5.03% 45.331 Thousand 67.3 Thousand -32.64% Total Puts 160.044 Thousand 319.155 Thousand -49.85% 51.14 Thousand 237.809 Thousand -78.5% PUT/CALL Ratio
NASDAQ:ARGXLong
by wallstreetsharks
Will ARGX break out ascending channelWill Argenx be Wall streets next Biotech unicorn? I am extremely bullish! Biotech is booming business. Monoclonal antibodies are revolutionizing pharma industry. Again great news for Argenx. 01feb2021 launches new global offering to raise funds after 'Go' decisions for CIDP treatment trials www.argenx.com www.argenx.com 02feb2021 Argenx raises $1 bln www.argenx.com statement showing their product is might be much better than competitors www.argenx.com Products are yet to be approved by FDA. Current products that are currently in clinical trials are: Efgartigumod Phase 3 trials submitted for Mystenias gravis/MG (1.4 million patients worldwide) Phase 3 trials ongoing for Immune Thrombocytopenia/ITP (200 thousand patients worldwide) Phase 2 trials ongoing for Chronic inflammatory Demyelinating polyneuropathy/CIDP (300 thousand patients worldwide) Phase 2 trials ongoing for Pemphigus Vulgaris/PV (200 thousand patients worldwide) This products aims to treat over 2 million patients worldwide. IF this products proves to have a high enough efficacy Argenx wil immediately have hit the jackpot. Cusatuzumab (in cooperation with J&J) Phase 2 trials ongoing for Accute Myeloid Leukemia (AML) (incidence 4.3 to 100.000 and a death rate 2.8 to 100.000 which is extremely high) At some point in our life we all have been confronted with cancer. Sayings like 'it always has to happen to the best of us' don't exist for nu reason. Curing cancer isn't only a billion dollar quest(ion). It's a matter of life and death. Phase 2 trials ongoing for Higher-risk Myelodysplastic Syndromes (MDS) (approximate prevalence op 150 thousand people affected worldwide) Cusatuzumab again might work out to become a flagship product product for Argenx. Argenx pipeline products show immense promise. The company's market cap is still on the low side compared to other pharma companies with working products. Possible upside to be a multiple of the current market cap. Current market cap. $16.695bln as of 03feb2021 Compared to other biotech companies as of 03feb2021 Alexion Pharmaceuticals $33.84 bln Regeneron: $52.41 bln Vertex Pharmaceuticals $54.84 bln Novo Nordisk $167.60 bln If Argenx keeps doing great, FDA approves efgartigumod and stock price remains in this ascending channel Stock will double within 2 years time. ARGX might even break out above this channel coming days
NASDAQ:ARGXLong
by DrSkeletor
argenx reports positive topline results from Phase 2The data showed a clinically meaningful and statistically significant benefit of ARGX-113 over placebo. In addition, ARGX-113 was found to have a favorable tolerability profile consistent with that observed in the Phase 1 study. “These data demonstrate a rapid and sustained benefit in disease score after treatment with ARGX-113, supporting further development of the drug as a potential new option to fill the current treatment gap for MG patients.” The Phase 2 double-blind, placebo-controlled, proof-of-concept trial enrolled 24 MG patients with generalized muscle weakness. The primary endpoints of the study were safety and tolerability. Primary endpoint analysis revealed ARGX-113 to be well tolerated in all patients. The secondary endpoint measures relating to efficacy showed ARGX-113 treatment resulted in rapid onset of action and strong clinical improvement over placebo during the entire duration of the study. 75% of patients treated with ARGX-113 had a clinically meaningful and statistically significant improvement. Patients in the treatment arm showed rapid disease improvement, with clear separation from placebo 1 week after the first infusion. ARGX-113 demonstrated strong clinical improvement over placebo as measured by all four predefined clinical efficacy scales. www.argenx.com
NASDAQ:ARGXEducation
by AlenCiken
Efgartigimod for Myasthenia Gravis- Phase 3Those who have the ability to ignore the noise and the roller coaster ride that the markets have brought upon us from early October to this day, you would be +80% on $ARGX. Nevertheless, if you were/are trading/playing it, it's a good play. Whether it's politics or economics, there's way too many factors in play so all things are considered, -awareness for the win. Biotech wise, there are only few variables that I need to ponder here. Short float is at 2.84% because a convincing phase3 data on ARGX-113 for Myasthenia Gravis, will blow the shorts. Not to mention Cusatuzumab for acute myeloid leukemia. These are just 2 of the many 2019 catalysts. Other key stats: 1) $500mm from the Janssen deal -$JNJ, 2) $10mm payment from Abbvie- (2018 preclinical milestone on ARGX-115), upon achievements of other milestones they're eligible for up to $625 million and double digit royalties upon commercialization. Overweight on Morgan Stanley, Jan 4th, '19. Buy on Goldman, Dec 17th, '18 Bottomline, I am watching this. You have to!
NASDAQ:ARGX
by UnknownUnicorn2993086